A Safety-Aware Clinical Evidence Mapping Approach for SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
Author :
Research Scholar Prasun Kumar Verma, Professor Dr.Ankit Singh, Dr.G.Vijaya KumarJourna Name:
International Journal of Science, Engineering and Technology Volume:
12 issue:5 Year:Volume-12-issue-5 Views : 35
Abstract:
Background: SGLT2 inhibitors and GLP-1 receptor agonists (GLP-1 RAs) support type 2 diabetes care through different mechanisms and have different safety concerns. Existing reviews summarize benefits, but brief clinical comparisons can overlook precautions that affect treatment discussions. Objective: To design and demonstrate a safety-aware evidence mapping approach using sources published during 2022–2024. Methods: We identified outcome and precaution statements in established guidance, a 2023 network meta-analysis and the 2024 FLOW trial. We developed a two-layer map: an outcome-priority layer and a medicine-specific safety-check layer. The approach was demonstrated using three fictional clinical profiles. Results: The implementation generated distinct review prompts for a heart-failure profile, a weight-management profile and a chronic-kidney-disease profile. All three required a safety check before clinical interpretation. The demonstration created no patient-level efficacy estimates or new relative treatment effects. Conclusion: A simple safety-aware map may improve the transparency of educational evidence summaries, but clinical validation and independent testing are necessary before use as a decision-support tool.
APA:Research Scholar Prasun Kumar Verma, Professor Dr.Ankit Singh, Dr.G.Vijaya Kumar. (Volume-12, Issue-5 -(Year-Volume-12-issue-5)). A Safety-Aware Clinical Evidence Mapping Approach for SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes. Retrieved from https://www.ijset.in/wp-content/uploads/ICGEMT.V12_issue_116.pdf
Chicago:Research Scholar Prasun Kumar Verma, Professor Dr.Ankit Singh, Dr.G.Vijaya Kumar. "A Safety-Aware Clinical Evidence Mapping Approach for SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes" Example, Volume-12-issue-5-Year-Volume-12-issue-5-2348-4098. https://www.ijset.in/wp-content/uploads/ICGEMT.V12_issue_116.pdf.